GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » 9-Day RSI

Novaccess Global (Novaccess Global) 9-Day RSI : 71.95 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-24), Novaccess Global's 9-Day RSI is 71.95.

The industry rank for Novaccess Global's 9-Day RSI or its related term are showing as below:

XSNX's 9-Day RSI is ranked worse than
94.9% of 1569 companies
in the Biotechnology industry
Industry Median: 43.98 vs XSNX: 71.95

Competitive Comparison of Novaccess Global's 9-Day RSI

For the Biotechnology subindustry, Novaccess Global's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novaccess Global's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novaccess Global's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Novaccess Global's 9-Day RSI falls into.



Novaccess Global  (OTCPK:XSNX) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novaccess Global  (OTCPK:XSNX) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Novaccess Global 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Novaccess Global's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Novaccess Global (Novaccess Global) Business Description

Traded in Other Exchanges
N/A
Address
8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404